1 / 53

CHOOSING THE RIGHT MEDICAL TREATMENT AND RECENT ADVANCES

CHOOSING THE RIGHT MEDICAL TREATMENT AND RECENT ADVANCES. NEELIMA THAKUR, MD. Epilepsy Burden. The lifetime likelihood of Experiencing at least 1 seizure is ~ 9%. Receiving a diagnosis of epilepsy is ~ 3%. Approximately 200,000 new cases of seizures and epilepsy occur each year.

debra-spence
Télécharger la présentation

CHOOSING THE RIGHT MEDICAL TREATMENT AND RECENT ADVANCES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHOOSING THE RIGHT MEDICAL TREATMENT AND RECENT ADVANCES NEELIMA THAKUR, MD.

  2. Epilepsy Burden • The lifetime likelihood of • Experiencing at least 1 seizure is ~ 9%. • Receiving a diagnosis of epilepsy is ~3%. • Approximately 200,000 new cases of seizures and epilepsy occur each year. • Epilepsy and seizures affect nearly 3 million Americans of all ages, at an estimated annual cost of $17.6 billion in direct and indirect costs.

  3. Seizures are defined as abnormal discharge of electrical activity from brain neurons resulting in transient loss of motor, sensory or mental function.

  4. Seizure types • Provoked seizures • Acute symptomatic. • Often a reversible cause. • By definition, these are notepilepsy. • Unprovoked seizures • 2 unprovoked seizures 24hrs apart is considered epilepsy.

  5. First unprovoked seizure – risk of seizure recurrence. • 24-74 % in first 5 years. • Normal EEG and imaging studies – 24% • Abnormal EEG and imaging studies- 74% • After 2nd unprovoked seizure – 80%

  6. First unprovoked seizure • Risk factors for seizure recurrence • Family history • Abnormal EEG • Abnormal neuroimaging. • Seizure in sleep.

  7. First unprovoked seizure • 50 % seizures recur in the first year • 80% with in two years.

  8. First unprovoked seizure • Current Guidelines • No antiepileptic drugs (AEDs) if • There are no other risk factors • Normal EEG.

  9. Anti epileptic Drugs

  10. Antiepileptic drugs 1st drug- 47 % seizure free 2nd drug- 13% seizure free 3rd / multi drugs -4% seizure free

  11. Epilepsy outcome at >7 years. • Seizure free >7years - 59 % • Seizure free >1 year and relapses- 16 %

  12. Which AED to choose?

  13. Anti epileptic Drugs • 1850 : Bromides • 1910: Phenobarbital • 1940: Phenytoin • 1950: Ethosuximide • 1958: ACTH • 1954: Primidone • 1968: Carbamazepine • 1975: Clonazepam • 1978: Depakote

  14. 1990s: Newer AEDs were developed. • lamotrigine (Lamictal) • felbamate (Felbatol) • levetiracetam (Keppra) • topiramate (Topamax) • oxcarbazepine (Trileptal) • zonisamide (Zonegran) • pregabalin (Lyrica) • lacosamide (Vimpat) • rufinamide (Banzel) • vigabatrin (Sabril) • clobazam (Onfi) • ezogabine (Potiga) • perampanel (Fycompa) • eslicarbazepine (Aptiom) • Good efficacy, • Fewer toxic effects, • Better tolerability

  15. Following criteria may be helpful • Type of epilepsy • Comorbidities • Side effect profile • Pharmacokinetics • Drug-drug interactions • Single dose-Compliance • Women • Elderly

  16. Type of epilepsy • Primarily generalized epilepsies. • ethosuximide ( Absence seizures) • valproate • topiramate • zonisamide • lamotrigine • levetiracetam • rufinamaide • clobazam • vigabatrin.

  17. Primarily generalized epilepsies • Avoid carbamazepine, gabapentin, Phenytoin.

  18. EfficacyPrimarily generalized epilepsy • Absence seizures • ethosuximide, valproate are effective than lamotrigine. • Atonic seizures : clobazam. • Primarily generalized epilepsies: valproate>topamax and leviteracetam.

  19. Type of epilepsy • Partial Epilepsies All AEDs except ethosuximide.

  20. Efficacy-Partial seizures • Not possible to compare efficacy as there are no major head to head trials. • The study population, inclusion and exclusion criteria are different. ‘

  21. Mechanism of action Rational polypharmacy.

  22. Comorbidities • Bipolar disorder/depression/anxiety: valproate, lamotrigine, carbamazepine, oxcarbazepine. • Migraines: valproate, topiramate, zonisamide. • Obesity: topiramate, zonisamide • Neuropathy: gabapentin, lyrica, carbamazepine, oxcarbazepine.

  23. ComorbiditiesAEDs to avoid • Psychiatric/behavorial problems: levetiracetam. • Osteoporosis: phenobarbital, phenytoin, valproate, carbamazepine. • Renal stones : topamax, zonegran. • Obesity: valproate, pregabalin, gabapentin. • Diabetes: valproate.

  24. Liver dysfunction Drugs of choice • leviteracetam • lacosamide • pregabalin • gabapentin

  25. Renal dysfunction Decrease drug doses that are cleared primarily by kidneys • levetiracetam • lacosamide • pregabalin • gabapentin

  26. Hemodialysis Risk of drug removal is high for non protein bound drugs Doses need to be adjusted accordingly. • High risk levetiracetam lacosamide phenobarbital topiramate. • Low risk phenytoin valproate lamotrigine. carbamazepine

  27. Drug interactions Liver enzyme(CYP 450 & UGT) inducers phenytoin, phenobarbital, carbamazepine, oxcarbazepine, topiramate, felbamate, rufinamide. • Liver enzyme inhibitors • valproate, felbamate.

  28. Single daily dose Improves Patient compliance. XR formulations may have lesser side effects. • Q day AEDs Phenytoin, Phenobarbital and zonegran. • XR formulation Depakote ER, Lamictal XR, Keppra XR, Oxtellar XR and Trokendi XR.

  29. Epilepsy in Elderly • The prevalence and incidence of epilepsy are highest in later life!! • Approximately 7% of seniors have epilepsy. • 25% of new cases occur in elderly

  30. AEDs : Elderly • Older people with a first unprovoked seizure are more likely to develop recurring seizures than are younger adults. • Starting AEDs after a single unprovoked seizure may be appropriate in some cases.

  31. AEDs: Elderly

  32. AEDs - Elderly TREAT CAUTIOUSLY! • Elderly are more susceptible to the adverse effects of drugs than their younger patients. • Pharmacokinetics and pharmacodynamics of AEDs differ in old age . • Drug-drug interactions

  33. AEDs- Elderly Treatment Challenges • Comorbidities complicate the treatment options. • Polypharmacy make them susceptible to drug interactions. • Adherencemay not be as good in elderly patients with epilepsy.

  34. AEDs - Elderly • Pharmacokinetic • Albumin results in free fraction phenytoin, carbamazepine and valproate. • Drug metabolism is affected by decreased liver enzymes. • Drug excretion is affected by decreased renal clearance.

  35. AEDs - Elderly • In general the preferred drugs are • levetiracetam • lamotrigine • gabapentin

  36. AEDs-Pregnancy Concerns • Effect of AEDs on Fetus and infant during • Pregnancy • Breast feeding. • AED pharmacokinetics affecting levels during • Pregnancy • Postpartum

  37. AEDs - Pregnancy Teratogenic risks mono vs polytherapy. • Single AED 3.1 % • Two AEDs 5.8 % • Three AEDs 8.3%

  38. AEDs - Pregnancy • Major malformations with monotherapy • valproate 9.3% • phenobarbital 5.5 % • topiramate 4.2 % • carbamazepine 3% • phenytoin 2.9% • levetiracetam 2.4% • lamotrigine 2.0%

  39. AEDs - Pregnancy • Pharmacokinetics lamotrigine & levetiracetam clearance during pregnancy level up to 50% of baseline. • Postpartum- clearance returns to baseline and drug levels. • Check monthly levels and adjust dose.

  40. AEDs - Pregnancy In general, levetiracetam, lamotrigine, oxcarbazepine and carbamazepine are considered relatively safe.

  41. Newer AEDs • Ezogabine (Potiga) • Perampanel (Fycompa) • Eslicarbazepine (Aptiom)

  42. Ezogabine (Potiga)2011 • Mechanism of action: Potassium Channel • Approved for add on treatment for Partial epilepsy. • It is the first neuronal potassium channel opener developed for the treatment of epilepsy .

  43. Ezogabine (Potiga) • Mechanism of action: Potassium Channel • Approved as add on treatment for Partial epilepsy . • First neuronal potassium channel opener developed for the treatment of epilepsy .

  44. Ezogabine (Potiga) Absorption and Metabolism: • Well absorbed. Food has no influence. • Not known whether excreted in human milk. • Metabolized in liver. • Dosage adjustment is required in patients with moderate and greater renal or hepatic impairment . • *urine bilirubin can show falsely elevated readings

  45. Ezogabine (Potiga) • Drug interactions • Carbamazepine, phenytoin may Potiga levels. • Potiga has no effect on other AED levels. • POTIGA may digoxin serum concentrations. • Alcohol systemic exposure to POTIGA

  46. Ezogabine (Potiga) Adverse reactions FDA warning blue skin discoloration and eye abnormalities characterized by pigment changes in the retina Initial and periodic eye exams are recommended. • Urinary retention • Neuropsychiatric symptoms- confusion, psychosis • QT interval prolongation

  47. Perampanel (Fycompa)2012 • Mechanism of action: AMPA glutamate receptor noncompetitive antagonist. • Approved as add on treatment for Partial epilepsy.

  48. Perampanel (Fycompa) • Absorption and Metabolism: • Well absorbed. Food has no influence. • Not known whether excreted in human milk. • Metabolized in liver. Dosage adjustment is required in patients with moderate and greater renal or hepatic impairment .

  49. Perampanel(Fycompa) Drug interactions • Does not effect other AEDs. • Enzyme inducers perampanel levels.

  50. Perampanel (Fycompa) • Adverse reactions • Neuro-psychiatric symptoms ( black box warning for aggression and hostility). • Dizziness , Somnolence fatigue, blurred vision. • Pregnancy category C

More Related